I was disappointed to hear that the LH trial is not being resumed at this time. It is a good opportunity from both a human suffering perspective as well as a business opportunity. We will likely hear about various LH effects for years to come. Hopefully a partnership opportunity will permit the resumption of that trial.
A preprint was published yesterday which gave the results of an investigation into cardiac impairment in individuals with Long Covid. Here are some excerpts and a link to the article.
Long Covid is associated with multiple symptoms and impairment in multiple organs. Cardiac impairment has been reported to varying degrees by varying methodologies in cross-sectional studies. Using cardiac magnetic resonance (CMR), we investigated the 12-month trajectory of cardiac impairment in individuals with Long Covid.
534 individuals with Long Covid underwent baseline CMR (T1 and T2 mapping, cardiac mass, volumes, function, and strain) and multi-organ MRI at 6 months since first post-COVID-19 symptoms and 330 were rescanned at 12.6 months if abnormal findings were reported at baseline. Symptoms, standardised questionnaires, and blood samples were collected at both timepoints.
Of individuals with Long Covid, 102/534 [19%] had cardiac impairment at baseline; 71/102 had complete paired data at 12 months. Of those, 58% presented with ongoing cardiac impairment at 12 months.
Conclusion: Cardiac impairment, other than myocarditis, is present in 1 in 5 individuals with Long Covid at 6 months, persisting in over half of those at 12 months. Cardiac-related blood biomarkers are unable to identify cardiac impairment in Long COVID.
https://www.medrxiv.org/content/10.1101/2022....22272610v1
A preprint was published yesterday which gave the results of an investigation into cardiac impairment in individuals with Long Covid. Here are some excerpts and a link to the article.
Long Covid is associated with multiple symptoms and impairment in multiple organs. Cardiac impairment has been reported to varying degrees by varying methodologies in cross-sectional studies. Using cardiac magnetic resonance (CMR), we investigated the 12-month trajectory of cardiac impairment in individuals with Long Covid.
534 individuals with Long Covid underwent baseline CMR (T1 and T2 mapping, cardiac mass, volumes, function, and strain) and multi-organ MRI at 6 months since first post-COVID-19 symptoms and 330 were rescanned at 12.6 months if abnormal findings were reported at baseline. Symptoms, standardised questionnaires, and blood samples were collected at both timepoints.
Of individuals with Long Covid, 102/534 [19%] had cardiac impairment at baseline; 71/102 had complete paired data at 12 months. Of those, 58% presented with ongoing cardiac impairment at 12 months.
Conclusion: Cardiac impairment, other than myocarditis, is present in 1 in 5 individuals with Long Covid at 6 months, persisting in over half of those at 12 months. Cardiac-related blood biomarkers are unable to identify cardiac impairment in Long COVID.
https://www.medrxiv.org/content/10.1101/2022....22272610v1
5
